ArticleUnited European gastroenterology journal2013
Effect of lansoprazole on the epigastric symptoms of functional dyspepsia (ELF study): A multicentre, prospective, randomized, double-blind, placebo-controlled clinical trial.
Article in United European gastroenterology journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 6 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Placebo response in pharmacological trials in patients with functional dyspepsia-A systematic review and meta-analysis.Neurogastroenterology and motility · 2023Pooled it
- Evidence-based clinical practice guidelines for functional dyspepsia 2021.Journal of gastroenterology · 2022Guideline
- Efficacy of Acupuncture Treatment for Postprandial Distress Syndrome: A Systematic Review and Meta-Analysis.Journal of immunology research · 2022Pooled it
- Proton pump inhibitors for functional dyspepsia.The Cochrane database of systematic reviews · 2017Pooled it
- ACG and CAG Clinical Guideline: Management of Dyspepsia.The American journal of gastroenterology · 2017Guideline
- Proton pump inhibitors for functional dyspepsia.The Cochrane database of systematic reviews · 2017Pooled it
- A Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial of Qi-Zhi-Wei-Tong Granules on Postprandial Distress Syndrome-Predominant Functional Dyspepsia.Chinese medical journal · 2018Trial
- Comprehensive Treatment of Functional Dyspepsia Using Traditional Chinese Medicine: A Review Based on Pathophysiological Perspectives.Drug design, development and therapy · 2025Review
- The Impact of Duodenal Mucosal Vulnerability in the Development of Epigastric Pain Syndrome in Functional Dyspepsia.International journal of molecular sciences · 2022Article
- Epidemiology and Clinical Characteristics Based on the Rome III and IV Criteria of Japanese Patients with Functional Dyspepsia.Journal of clinical medicine · 2022Article
- A comprehensive review of functional dyspepsia in pediatrics.Clinical journal of gastroenterology · 2022Review
- MODERN APPROACH TO DYSPEPSIA.Acta clinica Croatica · 2021Review
- United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia.United European gastroenterology journal · 2021Article
- Review
- Therapeutic strategy for the patients with coexisting gastroesophageal reflux disease and postprandial distress syndrome of functional dyspepsia.JGH open : an open access journal of gastroenterology and hepatology · 2020Article
- Efficacy and Safety of Clidinium/Chlordiazepoxide as an Add-on Therapy in Functional Dyspepsia: A Randomized, Controlled, Trial.Journal of neurogastroenterology and motility · 2020Article
- Clinical Practice Guidelines for Functional Dyspepsia in Korea.Journal of neurogastroenterology and motility · 2020Review
- The Application of the Rome IV Criteria to Functional Esophagogastroduodenal Disorders in Asia.Journal of neurogastroenterology and motility · 2017Review
- Functional dyspepsia: new insights into pathogenesis and therapy.The Korean journal of internal medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince the publication of the Rome III criteria for functional dyspepsia (FD), the evidence about the efficacy of half-dose of proton pump inhibitors for dyspepsia symptoms have been limited.
objectiveTo examine the efficacy of lansoprazole for functional dyspepsia (FD) diagnosed with the Rome III criteria by the multicentre, double-blind, randomized, placebo-controlled study in Japan.
methodsA total of 54 FD participants were randomized to lansoprazole 15 mg once daily or placebo for a 4-week double-blind treatment period. The primary efficacy endpoint was an overall dyspeptic symptom relief rate evaluated by 5-point Likert scale scores. The alteration of dyspeptic symptom scores during the study period was also assessed.
resultsAt week 4, the overall dyspeptic symptom relief rates were higher in the lansoprazole group (30.4%) than in the placebo group (6.7%) (p = 0.045). The scores for epigastric pain (p = 0.045) and epigastric burning (p = 0.03) were significantly improved in the lansoprazole group compared to the placebo group, whereas the improvement of the scores for postprandial fullness (p = 0.81) and early satiation (p = 0.33) was not different between lansoprazole and placebo groups.
conclusionsLansoprazole 15 mg ameliorates dyspeptic symptoms, particularly the epigastric pain syndrome-related symptoms of FD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.